↓ Skip to main content

VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results

Overview of attention for article published in Clinical Cancer Research, May 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
2 news outlets
twitter
23 X users

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
39 Mendeley